Celltrion Pharm

Celltrion Pharm, established in 1976, is a prominent entity within the Pharmaceuticals and Healthcare industries, dedicated to enhancing patient lives through the development and production of high-quality pharmaceuticals. The company specializes in both chemical drugs and advanced biosimilars, focusing on rigorous research and development to address unmet medical needs. With a global presence spanning Asia and the Asia Pacific region, Celltrion Pharm offers contract manufacturing services, leveraging its expertise to produce innovative treatments. Its product portfolio includes critical medicines for autoimmune disorders and various cancers, such as Remsima and Truxima, aiming to provide accessible therapeutic options. The company operates with a workforce of 500 - 1,000 employees, contributing to its extensive operational capabilities and market reach.

The firm's commitment extends beyond product development to encompass robust corporate responsibility. Celltrion Pharm has implemented an ESG committee to drive sustainability and strengthen its governance and social responsibility initiatives, reflecting a forward-thinking approach to business operations. This dedication to ethical practices and long-term value creation is integral to its corporate strategy. The company's operational scale and commitment to innovation are supported by its dedicated team, and further details can be explored by accessing Meet Celltrion Pharm's team to understand the leadership and personnel driving its success. The company's ticker symbol is KRX: 068760, and its official web presence is maintained at www.celltrionph.com.

Celltrion Pharm's product offerings are diverse, including pharmaceuticals, chemical compounds, and specific treatments for conditions like cancer and blood disorders, with a notable focus on breast cancer therapies. The company's revenue reached $285.0M,View more...